{
  "id": 1756,
  "text": "0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.\n\n<question>: ",
  "ChatGPT_response_0": "在这项随机对照试验中，顶替替卡培同环磷酰胺与单独使用环磷酰胺相比，患者的中位无进展生存期分别为2.8个月和4.8个月。研究结果表明，顶替替卡培同环磷酰胺疗法在无进展生存期方面表现更好。然而，在总生存期方面并未观察到明显差异。这项研究涉及患有国际妇产科联合会第四期B期、复发或持续宫颈癌的患者，旨在探讨不同治疗方案的疗效和安全性。",
  "query": "在一项涉及患有国际妇产科联合会第四期B期、复发或持续宫颈癌的患者的随机对照试验中，顶替替卡培同环磷酰胺与单用环磷酰胺相比有何不同？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在一项涉及患有国际妇产科联合会第四期B期、复发或持续宫颈癌的患者的随机对照试验中，顶替替卡培同环磷酰胺与单用环磷酰胺相比有何不同？\n\n<reference text>: 0 0 2 { \\mathrm { ) } }$ ).The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus combined regimen $\\mathrm ( p < 0 .0 0 1 \\} \\$ ).However, no OS difference was noted.In a RCT1633,1635 enrolling patients with FIGO stage IVB, recurrent, or persistent cervical cancer, topotecan plus cisplatin was compared with cisplatin monotherapy.\n\n<reply>: ",
  "response": "在这项随机对照试验中，顶替替卡培同环磷酰胺与单独使用环磷酰胺相比，患者的中位无进展生存期分别为2.8个月和4.8个月。研究结果表明，顶替替卡培同环磷酰胺疗法在无进展生存期方面表现更好。然而，在总生存期方面并未观察到明显差异。这项研究涉及患有国际妇产科联合会第四期B期、复发或持续宫颈癌的患者，旨在探讨不同治疗方案的疗效和安全性。"
}